論文 - 詳細
| RRC ID | 65544 |
|---|---|
| 著者 | Kobayashi Y, Sakura T, Miyawaki S, Toga K, Sogo S, Heike Y. |
| タイトル | A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia. |
| ジャーナル | Cancer Immunol Immunother |
| Abstract |
Wilms' tumor 1 (WT1) is a promising target of new immunotherapies for acute myeloid leukemia (AML) as well as for other cancers. OCV-501 is a helper peptide derived from the WT1 protein. OCV-501 induced OCV-501-specific Type 1 T-helper (Th1) responses dose-dependently and stimulated helper activity of the specific Th1 cells in peripheral blood mononuclear cells from healthy donors. OCV-501 also enhanced the increase in WT1-killer peptide-specific cytotoxic T lymphocytes. OCV-501 stimulated the OCV-501-specific Th1 clones in an HLA class-II restricted manner and formed a complex with HLA class-II protein. OCV-501-specific Th1 clones demonstrated significant OCV-501-specific cytolytic activity against OCV-501-pulsed B-lymphoblastoid cell line cells. Based on the pre-clinical results, phase 1 clinical trial was conducted. The result of this trial suggested that the subcutaneous administration of OCV-501 once weekly for 4 weeks at doses of 0.3, 1, and 3 mg in older patients with AML during complete remission was safe and well tolerated. The maximum tolerated dose was considered to be ≥3 mg. Of the nine subjects enrolled, neither relapse nor blast cells were observed during the study. Immunological responses were observed in OCV-501-specific delayed-type hypersensitivity test. This trial was registered at http://www.clinicaltrials.gov as NCT 01440920. |
| 巻・号 | 66(7) |
| ページ | 851-863 |
| 公開日 | 2017-7-1 |
| DOI | 10.1007/s00262-017-1981-3 |
| PII | 10.1007/s00262-017-1981-3 |
| PMID | 28321480 |
| PMC | PMC5489634 |
| MeSH | Aged Aged, 80 and over Cancer Vaccines / administration & dosage* Cancer Vaccines / immunology Cancer Vaccines / pharmacology Cell Line, Tumor Cohort Studies Dose-Response Relationship, Drug Female HLA-A2 Antigen / genetics HLA-DR beta-Chains / genetics Humans Leukemia, Myeloid, Acute / therapy* Lymphocyte Activation / drug effects Male Maximum Tolerated Dose Middle Aged Remission Induction T-Lymphocytes, Cytotoxic / drug effects T-Lymphocytes, Cytotoxic / immunology Th1 Cells / drug effects Th1 Cells / immunology Vaccines, Subunit / administration & dosage Vaccines, Subunit / immunology Vaccines, Subunit / pharmacology WT1 Proteins / administration & dosage* WT1 Proteins / immunology WT1 Proteins / pharmacology |
| IF | 5.442 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 4 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | B-lymphoblastoid cell lines |